RAPT: rapt.com Company Value to Net Income
RAPT Therapeutics, Inc. (RAPT) specializes in developing oral allergy treatments. This chart of stock quotes with the -9.40 indicator confirms balance sheet stability driven by strategic research funding. RAPT Therapeutics, Inc. (RAPT) is building a comprehensive treatment system for oncology and inflammation by implementing a platform to block pathogenic cells. Testing is expected to resume following FDA approval, with previous risks already priced in by investors.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_RAPT_-_RAPT-Therapeutics-Inc._-_PE-Multiple "RAPT: RAPT Therapeutics, Inc. Business Payback Period 07/04/2022 - 03/14/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for rapt.com (RAPT)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
Total Debt to Equity Ratio RAPT Therapeutics, Inc.|RAPT - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital RAPT Therapeutics Inc.|RAPT - Company Debts|Debt to Book Value Ratio RAPT Therapeutics Inc.|RAPT - Company Long-Term Debts|Short-Term Debt RAPT Therapeutics|Intermediate Coverage Ratio rapt.com
- earnings and market multiples details:
RAPT - Net Profit|Projected Future Earnings RAPT Therapeutics, Inc.|RAPT - Price to Earnings Ratio|Price to Expected Earnings Ratio RAPT Therapeutics|RAPT - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio RAPT Therapeutics, Inc.|RAPT - Operating profit before deduction of amortization|Earnings per share for the trailing year RAPT Therapeutics|RAPT - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months rapt.com|RAPT - Earnings growth in current year|Expected earnings per share trend next year RAPT Therapeutics, Inc.
- sales volume and revenue indicators:
Comprehensive company analysis:RAPT Therapeutics, Inc. RAPT
Fundamental asset selection requires a rigorous analysis of the ratio between market capitalization and net income. The P/E multiple measures the cost of one dollar of profit, determining investment attractiveness and the risk of overpayment. For RAPT Therapeutics, Inc. (RAPT), with its virtual R&D model, this metric reflects the market's valuation of clinical trial outsourcing efficiency. The P/E chart for the issuer allows investors to distinguish speculative growth from actual business strengthening.
Key competitors
P/E Multiple Argenx|Price to Earnings Ratio BNTX (BioNTech Group)|ABVX (abivax.com) - Company Value to Net Income|P/E Multiple ADMA (admabiologics.com)|Business Payback Period protagonist-inc.com (PTGX)|IMVT - Price to Earnings Ratio|Kiniksa Pharmaceuticals, Ltd. (KNSA) - Price to Earnings Ratio|Grifols Biemat (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotechnologies|Price to Earnings Ratio CLDX|P/E Multiple auriniapharma.com|Price to Earnings Ratio BioCryst Pharmaceuticals Inc (BCRX)|Vera Therapeutics - Price to Earnings Multiple|P/E Multiple DNTH (dianthustx.com)|Pharvaris Pharma (PHVS) - Market Cap to Earnings|AbCellera Biologics - P/E Multiple|tourmalinebio.com - Market Price to Net Income Ratio|Precigen (PGEN) - Price to Earnings Ratio|Pharming Group - Company Value to Net Income|Price to Earnings Ratio Nektar Therapeutics Inc|UPB (Upstream Pharma) - Market Price to Net Income Ratio|P/E Multiple ZBIO|P/E Multiple immunome.com (IMNM)|P/E Multiple GOSS (gossamerbio.com)|Business Payback Period KalVista Pharma (KALV)|SEPN - Price to Earnings Ratio|Business Payback Period Pieris Pharmaceuticals PVLA|SVRA (Savara Inc.) - Price to Earnings Ratio|Market Cap to Net Income RIGL (Rigel Pharmaceuticals)|ANAB (AnaptysBio) - P/E Multiple|ATXS (Astria Therapeutics, Inc.) - Market Price to Net Income Ratio|Price to Earnings Ratio engene.com (ENGN)|JBIO (Aerovate) - Company Value to Net Income|P/E Multiple ACRS (Aclaris Therapeutics)|Company Value to Net Income KYTX|Tiziana Life Sciences - P/E Multiple|CABA: Price to Earnings Ratio|VTYX: P/E Multiple|THTX (Theratechnologies, Inc) - Price to Earnings Ratio|AVTX (Avalo Therapeutics, Inc.) - P/E Multiple|P/E Multiple Eledon Pharmaceuticals|Price to Earnings Ratio Agenus Inc. (AGEN)|Price to Earnings Ratio Climb Bio Inc. CLYM|P/E Multiple ZURA (Zura Bio Ltd)|ATYR - Price to Earnings Ratio|ADAG - Price to Earnings Ratio|IMA - P/E Multiple|STTK: P/E Multiple|Equillium Bio (EQ) - P/E Multiple|CNTB (connectbiopharm.com) - P/E Multiple|IMUX: Company Value to Net Income|P/E Multiple ATRA|P/E Multiple InflaRx NV (IFRX)|X4 Pharmaceuticals, Inc. (XFOR) - Market Cap to Net Income|P/E Multiple adicetbio.com ACET|Celularity - P/E Multiple|Company Value to Net Income INMB (INmune Bio Corp)|BRNS (Barinthus Bio) - Price to Earnings Ratio|Market Cap to Net Income KZR (Kezar Life Sciences)|Price to Earnings Ratio SAB Biotherapeutics Inc.|Akari Therapeutics Plc - Market Cap to Net Income|Price to Earnings Ratio ENLV (Enlivex Therapeutics Ltd.)|Price to Earnings Ratio Q32 Bio Inc QTTB|Price to Earnings Ratio geovax.com GOVX|P/E Multiple edesabiotech.com EDSA|iBio Corporation - P/E Multiple|Company Value to Net Income CARM (carismatx.com)|XTL Biopharmaceuticals Ltd. (XTLB) - Price to Earnings Ratio|Bolt Bio (BOLT) - P/E Multiple|HCWB (HCW Biologics Inc) - P/E Multiple|Price to Earnings Ratio Aptevo Therapeutics (APVO)|P/E Multiple AIM|Market Price to Net Income Ratio ADTX|P/E Multiple GRI (GRI Bio Corporation)|P/E Multiple XORTX Corp XRTX|HIND - Price to Earnings Ratio|Revelation Biosciences (REVB) - Price to Earnings Ratio|INDP (Indaptus Therapeutics, Inc.) - Price to Earnings Ratio|Scinai Immunotherapeutics Ltd (SCNI) - P/E Multiple|CALI (CalciMedica Inc) - P/E Multiple|affimed.com - Market Cap to Net Income|Price to Earnings Ratio allakos.com (ALLK)|P/E Multiple HOOKIPA Pharma, Inc. (HOOK)|IGM Biosciences Inc. - Price to Earnings Ratio|iTeos Therapeutics, Inc. (ITOS) - Market Cap to Earnings|OCEA: Price to Earnings Ratio|Company Value to Net Income TCBP (TC BioPharm (Holdings) PLC)|THRD: P/E Multiple
